Astrazeneca PLC’s (AZN) Buy Rating Reaffirmed at Cantor Fitzgerald
Astrazeneca PLC (NYSE:AZN)‘s stock had its “buy” rating reaffirmed by Cantor Fitzgerald in a report issued on Tuesday.
AZN has been the topic of a number of other research reports. Bank of America Corp. set a $41.40 price target on shares of Astrazeneca PLC and gave the stock a “buy” rating in a report on Thursday, September 8th. Argus raised shares of Astrazeneca PLC from a “hold” rating to a “buy” rating and set a $38.00 price target on the stock in a report on Monday, August 29th. Piper Jaffray Cos. initiated coverage on shares of Astrazeneca PLC in a report on Friday, September 23rd. They issued an “overweight” rating on the stock. BNP Paribas cut shares of Astrazeneca PLC from an “outperform” rating to a “neutral” rating in a report on Tuesday, September 13th. Finally, Berenberg Bank reaffirmed a “buy” rating on shares of Astrazeneca PLC in a report on Sunday, September 11th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the stock. Astrazeneca PLC presently has an average rating of “Buy” and a consensus price target of $37.49.
Shares of Astrazeneca PLC (NYSE:AZN) traded down 1.30% during midday trading on Tuesday, reaching $32.57. The company had a trading volume of 5,415,371 shares. The company has a 50 day moving average price of $33.36 and a 200-day moving average price of $30.71. The firm has a market capitalization of $82.40 billion, a P/E ratio of 37.22 and a beta of 0.75. Astrazeneca PLC has a one year low of $26.97 and a one year high of $35.04.
Astrazeneca PLC (NYSE:AZN) last released its quarterly earnings results on Thursday, July 28th. The company reported $0.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.76 by $0.07. The business earned $5.60 billion during the quarter, compared to the consensus estimate of $5.56 billion. Astrazeneca PLC had a return on equity of 28.02% and a net margin of 9.23%. The company’s quarterly revenue was down 4.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.21 EPS. On average, analysts anticipate that Astrazeneca PLC will post $2.97 EPS for the current fiscal year.
The firm also recently declared a dividend, which was paid on Monday, September 12th. Shareholders of record on Friday, August 12th were given a dividend of $0.44 per share. The ex-dividend date was Wednesday, August 10th. Astrazeneca PLC’s payout ratio is 78.29%.
A number of hedge funds have recently bought and sold shares of the stock. Dodge & Cox raised its stake in Astrazeneca PLC by 24.9% in the second quarter. Dodge & Cox now owns 32,532,723 shares of the company’s stock valued at $982,163,000 after buying an additional 6,483,073 shares during the last quarter. Capital International Investors raised its stake in Astrazeneca PLC by 22.1% in the second quarter. Capital International Investors now owns 20,473,479 shares of the company’s stock valued at $618,094,000 after buying an additional 3,705,199 shares during the last quarter. Primecap Management Co. CA raised its stake in Astrazeneca PLC by 17.4% in the second quarter. Primecap Management Co. CA now owns 15,365,950 shares of the company’s stock valued at $463,898,000 after buying an additional 2,281,675 shares during the last quarter. BlackRock Investment Management LLC raised its stake in Astrazeneca PLC by 73.2% in the second quarter. BlackRock Investment Management LLC now owns 7,207,036 shares of the company’s stock valued at $217,580,000 after buying an additional 3,046,268 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in Astrazeneca PLC by 14.6% in the first quarter. Renaissance Technologies LLC now owns 5,682,800 shares of the company’s stock valued at $160,028,000 after buying an additional 723,100 shares during the last quarter. Institutional investors and hedge funds own 11.39% of the company’s stock.
Astrazeneca PLC Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Stock Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related stocks with our FREE daily email newsletter.